IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/ Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it. Transcript Q2 (August 2016) http://s2.q4cdn.com/790425727/files/doc_financials/2016/final-081116-intelgenx-q2-2016-financial-results-47950179-v.3.pdf With respect to other BD activities, we're clearly focusing right now in the business development area on bringing in new deals. For example at the recent BIO Conference, we met with 50 different pharmaceutical companies to discuss partnering opportunities, and we're currently in discussions with eight companies that are interested in RIZAPORT licenses, 17 companies that are interested in our Tadalafil product, three companies are interested in our schizophrenia drug, and five companies have expressed interest in a deal on Forfivo outside of the US. Presentation August 2016 http://s2.q4cdn.com/790425727/files/doc_presentations/2016/IGXT-Aug-22-Investor-Presentation.pdf IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the BrainAugust 22, 2016 http://www.intelgenx.com/investors/press-releases/press-release-details/2016/IntelGenx-Announces-Successful-Clinical-Study-for-Montelukast-for-the-Treatment-of-Degenerative-Diseases-of-the-Brain/default.aspx "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."